Hospital
Forrest City Arkansas Hospital Company LLC
Forrest City Arkansas Hospital Company LLC was paid $7.42M by Medicaid between Jan 2018 and Dec 2024, across 171 billing codes. Its largest line is 87636, Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B — 14% of everything it billed.
33Billing provider infoFORREST CITY ARKANSAS HOSPITAL COMPANY LLC
FORREST CITY, AR 72335
FORREST CITY, AR 72335
33aNPI1811912009assigned 07/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.42M
24GClaims397,053
24DCodes billed171
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#14 of 49
Median peer was paid$2.62M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COOPER, RANDY controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 57,774 | $947K | |
| 2019 | 60,952 | $1.05M | |
| 2020 | 46,806 | $767K | |
| 2021 | 50,431 | $956K | |
| 2022 | 53,359 | $1.25M | |
| 2023 | 73,984 | $1.42M | |
| 2024incomplete | 53,747 | $1.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 14% | 10,142 | 7,313 | $1.02M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 10% | 13,126 | 9,494 | $773K |
| 59025 | Fetal non-stress test | 7.1% | 3,702 | 2,343 | $526K |
| 80053 | Comprehensive metabolic panel | 6.1% | 30,154 | 21,412 | $456K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 4,740 | 3,607 | $379K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.1% | 3,395 | 1,623 | $307K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,248 | 1,661 | $254K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.4% | 3,371 | 2,902 | $253K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.0% | 35,390 | 24,669 | $225K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.0% | 12,231 | 9,541 | $225K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.6% | 5,015 | 3,807 | $190K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.3% | 19,498 | 10,573 | $167K |
159 more codes
| 99284 | Emergency room visit (serious) | 2.0% | 6,141 | $148K |
| 99285 | Emergency room visit (most serious) | 1.5% | 4,619 | $114K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 9,427 | $97K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 1,794 | $94K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 3,617 | $93K |
| 83880 | 1.2% | 3,912 | $91K | |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 14,702 | $91K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 1,256 | $88K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 12,231 | $80K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 4,601 | $76K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,251 | $71K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,781 | $71K |
| 84484 | <1% | 9,937 | $66K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 594 | $62K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,764 | $59K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,150 | $58K |
| 81025 | <1% | 7,753 | $53K | |
| 11043 | <1% | 596 | $52K | |
| 81001 | <1% | 14,524 | $45K | |
| 82962 | <1% | 8,055 | $44K | |
| 83874 | <1% | 4,010 | $43K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,722 | $40K |
| 82077 | <1% | 2,495 | $36K | |
| 87040 | <1% | 4,324 | $35K | |
| 87420 | <1% | 3,500 | $35K | |
| 87070 | <1% | 1,859 | $32K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,325 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,131 | $30K |
| 80061 | Lipid panel | <1% | 2,853 | $30K |
| 87081 | <1% | 3,432 | $30K | |
| 73630 | <1% | 1,376 | $28K | |
| 73560 | <1% | 1,452 | $28K | |
| 87077 | <1% | 3,200 | $24K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,894 | $24K |
| 73130 | <1% | 1,067 | $24K | |
| 83690 | <1% | 4,305 | $24K | |
| 82803 | <1% | 1,670 | $22K | |
| 81003 | <1% | 9,479 | $21K | |
| 87088 | <1% | 3,441 | $21K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 554 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,985 | $20K |
| 78453 | <1% | 174 | $19K | |
| 83605 | <1% | 2,710 | $18K | |
| 86901 | <1% | 931 | $18K | |
| 94060 | <1% | 1,377 | $17K | |
| 82247 | <1% | 2,815 | $16K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 774 | $16K |
| 94729 | <1% | 1,293 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 701 | $15K |
| 71250 | <1% | 177 | $15K | |
| 73610 | <1% | 841 | $14K | |
| 94726 | <1% | 1,192 | $14K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 536 | $14K |
| 83735 | <1% | 2,194 | $13K | |
| 80050 | General health panel | <1% | 271 | $13K |
| 72100 | <1% | 551 | $12K | |
| 94761 | <1% | 976 | $12K | |
| 85379 | <1% | 1,550 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 103 | $12K |
| 87186 | <1% | 3,127 | $12K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 106 | $12K |
| 84702 | <1% | 1,172 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,184 | $9K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 95 | $9K |
| 82150 | <1% | 1,642 | $9K | |
| 82550 | <1% | 1,859 | $8K | |
| 36600 | <1% | 376 | $8K | |
| 82553 | <1% | 1,124 | $8K | |
| 85027 | <1% | 2,045 | $8K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,704 | $8K |
| 74018 | <1% | 513 | $8K | |
| 73030 | <1% | 503 | $8K | |
| 71020 | <1% | 497 | $7K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 172 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,699 | $6K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 281 | $6K |
| 82565 | <1% | 451 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,147 | $5K |
| 85610 | <1% | 2,039 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,303 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,405 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,105 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 103 | $4K |
| 94760 | <1% | 505 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 30 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 99 | $4K |
| 71010 | <1% | 622 | $4K | |
| 86900 | <1% | 838 | $3K | |
| 77002 | <1% | 108 | $3K | |
| 73110 | <1% | 160 | $3K | |
| 85730 | <1% | 595 | $3K | |
| 84439 | <1% | 253 | $2K | |
| 86850 | <1% | 229 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,434 | $2K |
| 90715 | <1% | 118 | $2K | |
| 86141 | <1% | 209 | $2K | |
| 82248 | <1% | 294 | $2K | |
| 84436 | <1% | 294 | $2K | |
| 97597 | <1% | 98 | $1K | |
| 80179 | <1% | 85 | $1K | |
| 86140 | <1% | 352 | $1K | |
| 82009 | <1% | 284 | $1K | |
| 80143 | <1% | 67 | $1K | |
| 73502 | <1% | 61 | $1K | |
| 85651 | <1% | 343 | $842.44 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 607 | $820.48 |
| 84520 | <1% | 249 | $785.23 | |
| 84703 | <1% | 91 | $755.74 | |
| 83525 | <1% | 59 | $608.99 | |
| 82607 | <1% | 57 | $584.06 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 103 | $574.33 |
| 72040 | <1% | 28 | $465.88 | |
| 84134 | <1% | 29 | $462.81 | |
| 93971 | <1% | 20 | $449.43 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,633 | $426.79 |
| 82746 | <1% | 42 | $375.69 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 533 | $372.48 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 785 | $343.44 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 291 | $329.56 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 16 | $286.00 |
| 74000 | <1% | 17 | $270.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 316 | $240.83 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 111 | $240.27 |
| G0378 | Hospital observation service, per hour | <1% | 602 | $238.85 |
| 80185 | <1% | 14 | $237.38 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,979 | $203.41 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 18 | $194.26 |
| 87045 | <1% | 15 | $175.11 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 218 | $164.38 |
| 87899 | <1% | 13 | $141.57 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 77 | $139.01 |
| 82272 | <1% | 75 | $131.92 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 178 | $125.95 |
| 86592 | <1% | 36 | $114.61 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 309 | $112.82 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 886 | $112.12 |
| 87015 | <1% | 13 | $104.94 | |
| 80164 | <1% | 13 | $96.70 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 104 | $70.90 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,771 | $58.11 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 230 | $52.84 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 15 | $49.24 |
| 84100 | <1% | 20 | $47.46 | |
| 87046 | <1% | 13 | $37.07 | |
| 84156 | <1% | 26 | $31.50 | |
| 82570 | <1% | 13 | $29.56 | |
| 85018 | <1% | 37 | $27.04 | |
| 85014 | <1% | 34 | $27.04 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,642 | $11.40 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 140 | $8.01 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,659 | $0.03 |
| A9270 | Non-covered item or service | 0% | 172 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 646 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 83 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 13 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 39 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 248 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOPER, RANDY (SVP FINANCE OPERATIONS)
| Provider | Location | Paid |
|---|---|---|
| Jackson Hospital Corporation | Jackson, KY | $34.90M |
| Deming Hospital Corporation | Deming, NM | $34.61M |
| Hospital of Louisa, INC. | Louisa, KY | $27.77M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| Paintsville Hospital Company, LLC | Paintsville, KY | $15.46M |
| San Miguel Hospital Corporation | Las Vegas, NM | $13.21M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| MMC of Nevada LLC | Mesquite, NV | $2.60M |
| Fort Payne Hospital Corporation | Fort Payne, AL | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.